Trials
5 active
8 in total · 6 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are…”In the company’s words, NCT06284590 on ClinicalTrials.gov
- Tested for
- Malignant Melanoma, Melanoma Stage III, Melanoma Stage IV, Locally Advanced Basal Cell Carcinoma, FAP, Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma and 1 more
- Main trialPhase 3
- “Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.”In the company’s words, NCT02938299 on ClinicalTrials.gov
- Other names
- bifikafusp alfa · bifikafusp alfa + onfekafusp alfa
Other drugs for Malignant Melanoma
- PembrolizumabMerck & Co. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
- BCD-217Biocad · Phase 3
- ISCIB1+Scancell Ltd · Phase 3
Coming up4
- 31 May 2028Phase 1 trial completes · ClinicalTrials.gov
- Jul 2028Phase 2 trial completes · ClinicalTrials.gov
- Dec 2029Phase 1 trial completes · ClinicalTrials.gov
- Feb 2031Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Oct 2024 | Neoadjuvant L19IL2/L19TNF- Pivotal Study | |
| Phase 2Recruiting | Jul 2028 | Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients | |
| Phase 2Recruiting | Feb 2031 | L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) | |
| Phase 1Recruiting | 31 May 2028 | A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors | |
| Phase 1Not yet recruiting | Dec 2029 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors | |
| Phase 2Unknown | Sep 2024 | Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients | |
| Phase 1/2Unknown | 17 May 2016 | A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | |
| Phase 1/2Terminated | Sep 2023 | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026